Stock Price Quote

ZIM LABORATORIES LTD.

NSE : ZIMLABBSE : 541400ISIN CODE : INE518E01015Industry : Pharmaceuticals & DrugsHouse : MNC
BSE95.500.1 (+0.1 %)
PREV CLOSE ( ) 95.40
OPEN PRICE ( ) 96.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 22858
TODAY'S LOW / HIGH ( )94.50 97.50
52 WK LOW / HIGH ( )67.45 151.75
NSE94.95-0.55 (-0.58 %)
PREV CLOSE( ) 95.50
OPEN PRICE ( ) 95.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 94.95 (1943)
VOLUME 169532
TODAY'S LOW / HIGH( ) 94.10 97.45
52 WK LOW / HIGH ( )68.05 152.7
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1984
Management Info
Anwar Siraj Daud - Chairman Anwar Siraj Daud - Managing Director
Registered Office

Address Sadoday Gyan (Ground Floor), Opp. Nadt,Nelson Square, ,
Nagpur,
Maharashtra-440013

Phone 0712-2981960

Email infa@zimlab.in

Website www.zimlab.in

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, OTCEI

NEWS

29Jan Intimation Of Appointment Of Secretar
In compliance with Regulation 30 of SEBI (LODR) Regulations, 2015, we wo..
01Jan Zim Laboratories informs about details
Pursuant to Regulation 39(3) of the SEBI (LODR) Regulations, 2015, Zim L..
29Dec Zim Laboratories informs about closure
Zim Laboratories has informed that pursuant to the provisions of SEBI (P..
22Dec Zim Laboratories informs about loss of
Zim Laboratories has informed that it enclosed details of loss of share..
05Dec Zim Laboratories informs about loss of
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclo..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit48.2999999999999250.08
Gross Profit 70.0899999999999 359.17
Operating Profit 122.83576.2
Net Sales 958.193965.31

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26946.00 (0.74%)
M.Cap ( in Cr)57258.37
Sanofi India (BSE)
peergroup  8118.25 (2.06%)
M.Cap ( in Cr)18696.83
Dr. Reddy's Lab (BSE)
peergroup  6155.15 (1.78%)
M.Cap ( in Cr)102679.14
Divi's Lab (BSE)
peergroup  3436.75 (2.14%)
M.Cap ( in Cr)91234.91
Glaxosmithkline Phar (BSE)
peergroup  1943.10 (3.26%)
M.Cap ( in Cr)32917.29

Shareholding Pattern

NON-INSTITUTION 66.74%
PROMOTERS 33.26%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Zim Laboratories Ltd.

Zim Laboratories Ltd. was incorporated in the year 1984. Its today's share price is 95.5. Its current market capitalisation stands at Rs 465.33 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3965.31 Cr and Total Income of Rs.4029.62 Cr. The company's management includes Padmakar Shrinivas Joshi, Prakash Pralhadrao Sapkal, Niraj Pukhraj Dhadiwal, Zulfiquar Murtaza Kamal, Anwar Siraj Daud, Anwar Siraj Daud, Piyush Siddeshwar Nikhade, Kakasaheb Mahadik, Kamlesh Shende, Kavita Loya.

It is listed on the BSE with a BSE Code of 541400 , NSE with an NSE Symbol of ZIMLAB and ISIN of INE518E01015. It's Registered office is at Sadoday Gyan (Ground Floor), Opp. Nadt,Nelson Square, Nagpur-440013, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Paliwal Modani & Co, Raman S Shah & Co, SR Batliboi & Co LLP, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.